TScan Therapeutics (NASDAQ:TCRX – Get Rating) is one of 283 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it contrast to its peers? We will compare TScan Therapeutics to related companies based on the strength of its risk, earnings, profitability, analyst recommendations, dividends, institutional ownership and valuation. Risk & Volatility TScan […]
TScan Therapeutics (NASDAQ:TCRX – Get Rating) and Caribou Biosciences (NASDAQ:CRBU – Get Rating) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, dividends, earnings, profitability, valuation, institutional ownership and risk. Risk and Volatility TScan Therapeutics has a beta of […]
TScan Therapeutics (NASDAQ:TCRX – Get Rating) is one of 281 public companies in the “Biological products, except diagnostic” industry, but how does it weigh in compared to its peers? We will compare TScan Therapeutics to related companies based on the strength of its profitability, analyst recommendations, valuation, risk, earnings, dividends and institutional ownership. Analyst Recommendations […]
TScan Therapeutics, Inc. (NASDAQ:TCRX – Get Rating) saw a significant decline in short interest in May. As of May 31st, there was short interest totalling 134,500 shares, a decline of 41.9% from the May 15th total of 231,600 shares. Approximately 1.5% of the shares of the stock are short sold. Based on an average daily […]
TScan Therapeutics, Inc. (NASDAQ:TCRX – Get Rating) CEO David P. Southwell acquired 25,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 18th. The shares were purchased at an average cost of $3.59 per share, for a total transaction of $89,750.00. Following the completion of the acquisition, the chief executive officer […]